About
Novel oral small-molecule therapies for retinal degenerative disease; lead candidate tinlarebant (RBP4 inhibitor) in Phase 3 for Stargardt and GA. Valuation surpassed $2B after positive Phase 3 interim data.
HQ: US (listed NASDAQ: BLTE)
Funding
$350M public offering; market cap >$2B
—